Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 6, 2012, Pages 487-499

  Palayoor, Sanjeewani T ^a   J Aryankalayil, Molykutty ^a   Makinde, Adeola Y ^a   Cerna, David ^a   Falduto, Michael T ^b   Magnuson, Scott R ^b   Coleman, C Norman ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GenUs BioSystems Inc   (United States)

Author keywords

cardiovascular genes; CASMC; HCAEC; microarray; NSAIDs

Indexed keywords

CELECOXIB; IBUPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CARDIOVASCULAR FUNCTION; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY ENDOTHELIUM CELL; CORONARY ARTERY SMOOTH MUSCLE CELL; CYTOTOXICITY; DRUG EFFICACY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERTENSION; INFLAMMATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; THROMBOSIS; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IBUPROFEN; MICROARRAY ANALYSIS; MOLECULAR TARGETED THERAPY; MUSCLE, SMOOTH, VASCULAR; NITROBENZENES; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES;

EID: 84862235497     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31824ba6b5     Document Type: Article

References (43)

1. Milas L, Mason KA, Crane CH, et al. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Williston Park). 2003;17(suppl 5):15-24.
2. Teicher BA, Bump EA, Palayoor S, et al. Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. Rad Oncol Invest. 1996;4:221-230.
3. Lin HP, Kulp SK, Tseng PH, et al. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther. 2004;3:1671-1680.
4. Raju U, Nakata E, Yang P, et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations. Int J Radiat Oncol Biol Phys. 2002;54: 886-894.
5. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-2072.
6. Tseng WW, Deganutti A, Chen MN, et al. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genesand slows tumor growth in human pancreatic cancer. J Gastrointest Surg. 2002;6:838-843; discussion 44.
7. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-1423.
8. Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 2004;64:2030-2038.
9. Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98:736-747.
10. Palayoor ST, Bump EA, Calderwood SK, et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res. 1998;4:763-771.
11. Palayoor ST, Burgos MA, Shoaibi A, et al. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxiainducible factors by loss of von Hippel-Lindau tumor suppressor gene function. Clin Cancer Res. 2004;10:4158-4164.
12. John-Aryankalayil M, Palayoor ST, Cerna D, et al. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther. 2009; 8:261-273; PMCID: 2861287.
13. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899.
14. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
15. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA. 2000;284: 1247-1255.
16. Brophy JM. Cardiovascular risk associated with celecoxib. N Engl J Med. 2005;352:2648-2650.
17. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation. 2008;117:2104-2113.
18. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: Population based nested case-control analysis. BMJ. 2005;330:1366.
19. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-Analysis of randomised trials. BMJ. 2006;332:1302-1308.
20. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study. Circulation. 2011;123: 2226-2235.
21. Andrews J, Djakiew D, Krygier S, et al. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol. 2002;50: 277-284.
22. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96: 272-277.
23. John-Aryankalayil M, Palayoor ST, Cerna D, et al. Fractionated radiation therapy can induce a molecular profile for therapeutic targeting. Radiat Res. 2010;174:446-458.
24. Niederberger E, Manderscheid C, Grosch S, et al. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol. 2004;68:341-350.
25. Park MK, Kim MK, Kim JC, et al. Pattern of apoptosis by NS398, a selective COX-2 inhibitor, in hepatocellular carcinoma cell lines. Cancer Res Treat. 2005;37:313-317.
26. Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther. 2008;324: 749-758.
27. Baskar R, Sparatore A, Del Soldato P, et al. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur J Pharmacol. 2008;594:1-8.
28. Marra DE, Simoncini T, Liao JK. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21 (Waf1) and p27(Kip1). Circulation. 2000;102:2124-2130.
29. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007;14:55-61.
30. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15:254-259.
31. Viles-Gonzalez JF, Fuster V, Badimon JJ. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med. 2006;6:489-499.
32. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988; 53:505-518.
33. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129:307-321.
34. Kassam G, Le BH, Choi KS, et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry. 1998;37:16958-16966.
35. Lee CW, Ahn JM, Park DW, et al. Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty. Atherosclerosis. 2008;196:327-332.
36. Cirino G, Vergnolle N. Proteinase-Activated receptors (PARs): Crossroads between innate immunity and coagulation. Curr Opin Pharmacol. 2006; 6:428-434.
37. Coughlin SR. Thrombin signalling and protease-Activated receptors. Nature. 2000;407:258-264.
38. Gudmundsdottir IJ, Megson IL, Kell JS, et al. Direct vascular effects of protease-Activated receptor type 1 agonism in vivo in humans. Circulation. 2006;114:1625-1632.
39. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74:597-607.
40. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
41. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res. 2005;96:e1-e6.
42. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost. 2004;30:31-44.
43. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost. 2006;32(Suppl 1):61-68.